Breath-Based Sensor (LivSens) Shows Promise for Screening HE: JHE | August 2026
Hepatic encephalopathy (HE) is usually diagnosed through clinical assessment and psychometric testing, but these approaches can be time-consuming and require trained personnel. LivSens is a portable multisensor breath-analysis platform designed to detect HE-associated breath signatures using volatile organic compounds and a dedicated ZnO-based ammonia sensor.
Why was this study needed?
HE lacks a simple, rapid, non-invasive bedside screening tool.
Exhaled breath reflects systemic metabolic changes and contains potentially useful VOC biomarkers.
Ammonia is relevant to HE but is not sufficiently specific when used alone.
Combining ammonia with a broader VOC breathprint may improve discrimination.
Results:
The pilot study included 24 participants: 12 with HE and 12 healthy controls.
The ZnO ammonia sensor significantly differentiated HE from controls (P = 0.00019).
Sensor fusion showed reasonable agreement with serum ammonia, with RMSE around 22 µg/L.
Random Forest classification achieved 95.8% accuracy, 91.7% sensitivity, and 100% specificity in leave-one-out validation.
Clinical Impact:
The key innovation is not simply breath ammonia measurement, but a multisensor breathprint approach integrating ammonia, multiple VOC sensors, CO₂, humidity, temperature, and pressure. The ZnO sensor was the dominant contributor, but the full array improved overall classification performance compared with ammonia sensing alone.
However, this remains an early feasibility study. HE patients were compared only with healthy controls, so the system has not yet been tested against important clinical mimics or confounders such as renal dysfunction, other liver diseases, infection, or altered oral microbiota. The authors appropriately emphasize the need for larger multicentre validation.
Bottom Line:
LivSens demonstrated that a portable multisensor breath-analysis platform can distinguish patients with hepatic encephalopathy from healthy controls with promising preliminary accuracy. The concept is attractive for rapid, non-invasive HE screening, but larger disease-controlled studies are essential before clinical use.
